^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986148

    i
    Other names: BMS-986148, BMS986148, BMS 986148
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    Tubulin inhibitor, Mesothelin-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    9d
    Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer. (PubMed, Iran J Pharm Res)
    This review summarizes a range of ADCs targeting tumor-associated antigens in ovarian cancer, including mirvetuximab soravtansine (MIRV), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), sacituzumab tirumotecan (SKB-264), PF-06664178, anetumab ravtansine (BAY 94-9343), BMS-986148, DMOT4039A, RC88, lifastuzumab vedotin (DNIB0600A), upifitamab rilsodotin (ABBV-181), ZW220, DMUC4064A, and sofituzumab vedotin (DMUC5754A). The ADCs hold significant potential to reshape the treatment landscape for ovarian cancer by providing targeted therapeutic options. Further research is required to optimize patient selection, address resistance mechanisms, and improve safety profiles.
    Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Elahere (mirvetuximab soravtansine-gynx) • budigalimab (ABBV-181) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan) • anetumab ravtansine (BAY 94-9343) • upifitamab rilsodotin (XMT-1536) • RG7600 • lifastuzumab vedotin (DNIB0600A) • RG7882 • ZW220 • BMS-986148
    4years
    A Study of BMS-986148 in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=126, Terminated, Bristol-Myers Squibb | N=407 --> 126 | Active, not recruiting --> Terminated; Study terminated for business reasons not related to safety.
    Clinical • Enrollment change • Trial termination
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Opdivo (nivolumab) • BMS-986148
    4years
    Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. (PubMed, Clin Cancer Res)
    BMS-986148 {plus minus} nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.
    Clinical • P1/2 data • Journal • Combination therapy • PD(L)-1 Biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    Opdivo (nivolumab) • BMS-986148